{
 "title": "Tirzepatide news desk, September 18 to November 9, 2026",
 "publisher": "Tirzepatide Ranked (S.J Partners LLC)",
 "license": "CC BY 4.0",
 "as_of": "2026-11-09",
 "items": [
  {
   "event_date": "2026-11-09",
   "category": "FDA and regulation",
   "title": "No final FDA decision yet on the 503B proposal for tirzepatide",
   "summary": "A Federal Register search on November 9, 2026 found no final notice on the FDA’s April 30, 2026 proposal not to place tirzepatide, semaglutide or liraglutide on the 503B bulks list (91 FR 23431). Comments closed on July 30, 2026.",
   "cash_pay_impact": "503A pharmacies that compound for individual prescriptions are not covered by the proposal; programs that rely on 503B outsourcing facilities would need another source if it becomes final.",
   "source": "https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal",
   "confidence": "confirmed"
  },
  {
   "event_date": "2026-11-06",
   "category": "Pricing and access",
   "title": "NexLife lowers its compounded tirzepatide prices",
   "summary": "NexLife’s plan pages now list compounded tirzepatide at $129 a month month to month and $125, $119 and $115 a month on 3-, 6- and 12-month plans, and semaglutide at $109, $105, $99 and $95. Its microdose plans followed on November 8 at the same prices.",
   "cash_pay_impact": "A 12-month tirzepatide plan now comes to $1,380 at the listed rate. NexLife stays our #1 pick; three programs in our index still list a lower monthly figure.",
   "source": "https://nexlife.us/pages/tirzepatide-all-plans",
   "confidence": "confirmed"
  },
  {
   "event_date": "2026-11-06",
   "category": "Manufacturer and product updates",
   "title": "Lilly and Hims & Hers: Zepbound and Foundayo at Lilly's self-pay prices on the Hims platform",
   "summary": "In a joint release, Lilly and Hims & Hers said Hims patients can buy Zepbound from $299 and Foundayo from $149 at Lilly’s self-pay prices without leaving the platform, and Hims committed not to offer compounded copies of Lilly’s GLP-1s.",
   "cash_pay_impact": "Brand prices did not fall; the channel changed. Hims’ own fees for these patients were not stated in the release. Read our analysis.",
   "source": "https://investors.hims.com/news/news-details/2026/Lilly-and-Hims--Hers-expand-access-to-FDA-approved-Lilly-medicines/default.aspx",
   "confidence": "confirmed"
  },
  {
   "event_date": "2026-10-15",
   "category": "Pricing and access",
   "title": "Medicare Open Enrollment runs to December 7",
   "summary": "Medicare Open Enrollment for 2027 plans opened on October 15 and runs to December 7, 2026, per Medicare.gov. The GLP-1 Bridge ($50 a month) runs to December 31, 2027 and covers Wegovy, Foundayo and the Zepbound KwikPen only.",
   "cash_pay_impact": "People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; their Part D plan might cover a GLP-1, so compare plan formularies before December 7.",
   "source": "https://www.medicare.gov/basics/get-started-with-medicare/get-more-coverage/joining-a-plan",
   "confidence": "confirmed"
  },
  {
   "event_date": "2026-10-13",
   "category": "Pricing and access",
   "title": "Walmart to cover Ozempic and Mounjaro for employees with type 2 diabetes in 2027",
   "summary": "CNBC reported that Walmart will cover more than 250 prescriptions at no cost to employees in 2027, including Ozempic and Mounjaro for type 2 diabetes after prior authorization, while still not covering GLP-1s for weight loss.",
   "cash_pay_impact": "Employees seeking a GLP-1 for weight loss alone stay in the self-pay market. This is from news reporting, not a Walmart plan document.",
   "source": "https://www.cnbc.com/2026/10/13/walmart-glp-1s-inhalers-insulin-employee-benefits.html",
   "confidence": "reported"
  },
  {
   "event_date": "2026-10-12",
   "category": "Pricing and access",
   "title": "Ozari Health adds a second compounded GLP-1 plan",
   "summary": "A paid press release said Ozari One lists compounded tirzepatide with B12 at $125 a month billed every three months, everywhere except California, and Ozari Select lists tirzepatide from $235 down to $140 a month by plan length.",
   "cash_pay_impact": "Ozari is not yet in our price index; these figures come from a press release, not a first-party read.",
   "source": "https://www.globenewswire.com/news-release/2026/10/12/3378977/0/en/ozari-health-expands-nationwide-glp-1-telehealth-platform-with-two-plans-for-compounded-semaglutide-and-tirzepatide-starting-at-86-per-month.html",
   "confidence": "reported"
  },
  {
   "event_date": "2026-10-01",
   "category": "FDA and regulation",
   "title": "FDA updates its page on unapproved GLP-1 drugs",
   "summary": "The FDA’s page on concerns with unapproved GLP-1 drugs, current as of October 1, 2026, adds telehealth red flags, a 28-day discard rule for compounded multi-dose GLP-1 vials, and a statement that retatrutide and cagrilintide cannot be used in compounding under federal law.",
   "cash_pay_impact": "If you use a compounded multi-dose vial, discard it 28 days after first use, and treat any offer of compounded retatrutide as a red flag.",
   "source": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss",
   "confidence": "confirmed"
  },
  {
   "event_date": "2026-10-01",
   "category": "Pricing and access",
   "title": "Rhode Island Medicaid stops covering GLP-1s prescribed only for weight loss",
   "summary": "From October 1, 2026, Rhode Island Medicaid no longer covers Foundayo, Saxenda, Wegovy or Zepbound when prescribed solely for weight loss; coverage continues for type 2 diabetes and other approved uses, per a Medicaid plan provider notice.",
   "cash_pay_impact": "Affected members must switch to self-pay or to a covered indication with their clinician.",
   "source": "https://www.point32health.org/provider/coverage-glp-1s-tufts-health-ritogether-members-092026",
   "confidence": "confirmed"
  },
  {
   "event_date": "2026-09-29",
   "category": "Pricing and access",
   "title": "CMS: Medicare GLP-1 Bridge runs through 2027",
   "summary": "CMS’s BALANCE page (modified September 29, 2026) says the Medicare GLP-1 Bridge has been extended through December 31, 2027, and answers an FAQ about “the BALANCE Model not launching in Medicare in 2027”.",
   "cash_pay_impact": "Eligible Part D enrollees keep the $50 copay through 2027.",
   "source": "https://www.cms.gov/priorities/innovation/innovation-models/balance",
   "confidence": "confirmed"
  },
  {
   "event_date": "2026-09-18",
   "category": "Pharmacy recalls and warning letters",
   "title": "FDA warning letter 738238 to Empower Pharmacy",
   "summary": "The FDA’s warning letter to Empower Pharmacy (dated September 18, posted September 22, 2026) says its compounded tirzepatide with niacinamide and semaglutide with cyanocobalamin “appear to be essentially copies of FDA-approved semaglutide and tirzepatide products” and cites insanitary conditions.",
   "cash_pay_impact": "Ask any program which pharmacy fills your prescription and whether it has received a warning letter.",
   "source": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026",
   "confidence": "confirmed"
  }
 ]
}